Alliance to Host Capitol Hill Forum

Alliance to Host Capitol Hill Forum

The Alliance for Safe Biologic Medicines and Bloomberg Government will host a lunchtime Biosimilars Forum on Capitol Hill this coming Monday, February 27th, 2012 to discuss the FDA’s draft guidance documents on biosimilar product development.

Panelists include:

Brian Rye, Health-Care Financial Analyst with Bloomberg Government (moderator)

Dr. Richard Dolinar, Chairman of the Alliance for Safe Biologic Medicines

Dr. David Charles, Chief Medical Officer, Vanderbilt Neuroscience Institute, Chairman of the Alliance for Patient Access, and ASBM member partner

Seth Ginsberg, Co-Founder and President of the Global Health Living Foundation, and ASBM member partner

Andrew Spiegel, CEO and co-founder of the Colon Cancer Alliance, and ASBM member partner

Martha Raymond, Patient Advocate, Colon Cancer Alliance

Jeffrey P. Kushan, Partner, Sidley-Austin LLP

Location: Capitol Hill Visitors’ Center, Room 203-02
Date: February 27, 2012
Time: Noon

Please RSVP to rsvp@safebiologics.org by Friday, February 24 to attend.

Latest News

April 2024 Newsletter

ASBM’s Michael Reilly: Preserve the US Interchangeable Standard that Has Helped Drive Physician and Patient Confidence in Biosimilars In an April interview with EndpointsNews, an FDA official called on Congress to eliminate the distinction between biosimilars (which can be prescribed in place of their reference products by a physician) and “interchangeable” biosimilars, which can be substituted by pharmacists the […]

March 2024 Newsletter

Biden Administration HHS Budget Would Permit Third-Party Substitution of All Biosimilars On March 11th, the Biden Administration released its FY25 HHS Budget. In response, ASBM Executive Director Michael Reilly published a blog post sharing his concerns with the Administration’s proposal to permit widespread automatic (pharmacy-level) substitution of all biosimilars in place of their reference products; without physician approval […]

ASBM’s Michael Reilly: Preserve the US Interchangeable Standard that Has Helped Drive Physician and Patient Confidence in Biosimilars

In an April interview with EndpointsNews, an FDA official called on Congress to eliminate the distinction between biosimilars (which can be prescribed in place of their reference products by a physician) and “interchangeable” biosimilars, which can be substituted by pharmacists the way generics are. Doing so would undermine physician confidence in biosimilars and jeopardize treatment stability for many […]